OSU Wexner Medical Center

CLINICAL TRIALS

CLINICAL TRIALS

Nurix is working expeditiously to translate the science of targeted protein degradation into drug candidates with the potential to become breakthrough therapies.

City of Hope Duarte, California, 91010

Colorado Blood Institute Denver, Colorado, 80218

University of Miami Coral Gables, Florida, 33146

Florida Cancer Specialists Sarasota, Florida, 34232

Fort Wayne Oncology and Hematology Fort Wayne, Indiana, 46804

Hematology Oncology of Indiana Indianapolis, Indiana, 46260

University of Iowa Iowa City, Iowa, 52242

Maryland Oncology Hematology Silver Spring, Maryland, 20904

Karmanos Cancer Center Detroit, Michigan, 48201

Duke University Durham, North Carolina, 27705

Novant Health Cancer Institute Winston-Salem, North Carolina, 27103

University of Cincinnati Cincinnati, Ohio, 45221

Oncology Hematology Care Fairfield, Ohio, 45014

UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, 15232

SCRI Oncology Partners Nashville, Tennessee, 37203

Texas Oncology – Center South Austin, Texas, 78705

University of Utah Salt Lake City, Utah, 84112

Virginia Cancer Specialists, PC Fairfax, Virginia, 22031

Virginia Oncology Associates Norfolk, Virginia, 23502

CHU de Nantes Nantes, 44000

Pratia Hematologia Sp. z o.o. Katowice, 40-519

Pratia S.A. Krakow, 30-225

Aidport Sp. z o.o. Skorzewo, 60-185

Pratia Warszawa / Pratia MTZ Warsaw, 02-172

The Royal Marsden NHS Foundation Trust London, SW3 6JJ

The Christie NHS Foundation Trust Manchester, M20 4BX

Oxford University Hospitals NHS Foundation Trust Headington, Oxford, OX3 9D

Azienda Ospedaliero–Universitaria di Alessandria SS. Antonio e Biagio e Cesare Arrigo Alessandria, 15121

IRCCS Azienda Ospedaliero–Universitaria di Bologna, Policlinico di Sant’Orsola Bologna, 40138

Ospedale San Raffaele S.r.l. Milan, 20132

AUSL della Romagna UO Ematologia Ravenna, 48121

View Study

City of Hope Duarte, California, 91010

University of California, San Francisco San Francisco, California, 94143

Colorado Blood Cancer Institute Denver, Colorado, 80218

Yale Cancer Center New Haven, Connecticut, 06510

University of Miami Miami, Florida, 33136

Florida Cancer Specialists Sarasota, Florida, 34232

Winship Cancer Institute of Emory University Atlanta, Georgia, 30322

Northwestern University Chicago, Illinois, 60611

National Institute of Health Bethesda, Maryland, 20814

Duke University Medical Center Durham, North Carolina, 27705

University of Cincinnati Medical Center Cincinnati, Ohio, 45219

Cleveland Clinic Cleveland, Ohio, 44195

University of Pennsylvania, Abramson Cancer Center Philadelphia, Pennsylvania, 19104

MD Anderson Cancer Center Houston, Texas, 77030

Medical College of Wisconsin Milwaukee, Wisconsin, 53226

CHU Angers Angers, 49933

Hôpital Avicenne Bobigny, 93009

CHU de Nantes Nantes, 44093

CHU Bordeaux Pessac, 33604

CHU de Poitiers Poitiers, 86021

Institut Curie–Site Saint–Cloud Saint-Cloud, 92210

CHRU de Nancy Vandœuvre-lès-Nancy, 54500

IRCCS Ospedale San Raffaele Milan, 20132

Fondazione Policlinico Universitario A. Gemelli IRCCS Rome, 00168

Radboud University Medical Center Nijmegen, 6525 GA

Erasmus MC Rotterdam, 3015 GD

University Medical Center Utrecht Utrecht, 3584 CX

Medical University of Lublin Lublin, 20-090

AidPort sp. Zo.o Skórzewo, Greater Poland Voivodeship, 60-185

Pratia MCM Krakow, Lesser Poland Voivodeship, 30-272

University Clinical Hostpital in Wroclaw Wroclaw, Lower Silesian Voivodeship, 50-367

Pratia MTZ Warsaw, Masovian Voivodeship, 02-172

National Institute of Oncology Warszawa Warsaw, Masovian Voivodeship, 02-781

Pratia Onkologia Katowice Katowice, Silesian Voivodeship, 40-519

Hospital Universitari Vall d’Hebron Barcelona, 08035

Hospital Clínic de Barcelona Barcelona, 08036

Hospital Universitario de Cabuenes Gijón, 33203

Hospital Ramón y Cajal Madrid, 28034

Hospital Fundación Jimenez Díaz – START Madrid Madrid, 28040

Universitätsspital Basel Basel, 4031

Istituto Oncologico della Svizzera Italiana Bellinzona

University Hospital Zurich Zurich, 8091

St. James Hospital Leeds, LS9 7TF

Clatterbridge Cancer Center NHS Foundation Trust Liverpool, L7 8YA

St. Bartholomew’s Hospital, Barts NHS Trust London, EC1A 7BE

Sarah Cannon Research Institute UK London, W1G 6AD

The Christie NHS Foundation Trust Manchester, M20 4BX

Oxford University Hospitals NHS Foundation Trust Oxford, OX3 7LE

University Hospitals Plymouth NHS Trust Plymouth, PL6 8DH

University Hospital Southampton NHS Foundation Trust Southampton, SO16 6YD

Royal Marsden NHS Foundation Trust Sutton, SM2 5PT

The Beatson WOS Cancer Center Glasgow, Scotland, G12 0YN

View Study

City of Hope Duarte, California, 91010

Sarah Cannon Research Institute at Colorado Blood Cancer Institute Denver, Colorado, 80218

The University of Chicago Medical Center Chicago, Illinois, 60637

National Institutes of Health Clinical Center Bethesda, Maryland, 20814

Tennessee Oncology Nashville, Tennessee, 37203

MD Anderson Cancer Center Houston, Texas, 77030

Huntsman Cancer Institute, University of Utah Salt Lake City, Utah, 84112

View Study

University of Southern California Los Angeles, California, 90007

University of California, San Francisco San Francisco, California, 94158

University of Colorado School of Medicine Aurora, Colorado, 80045

University of Chicago Chicago, Illinois, 60637

University of North Carolina Chapel Hill, North Carolina, 27599

University of Oklahoma Oklahoma City, Oklahoma, 73104

MD Anderson Cancer Center Houston, Texas, 77030

University of Virginia Charlottesville, Virginia, 22908

Fred Hutchinson Cancer Center Seattle, Washington, 98109

Addenbrookes Cambridge University Hospital Cambridge, CB2 0QQ

Beatson West of Scotland Cancer Centre Glasgow, G12 0YN

Sarah Cannon Research Institute London, W1G 6AD

The Christie NHS Foundation Trust Manchester, M20 4BX

Northern Centre for Cancer Care Newcastle, NE7 7DN

Royal Marsden Hospital NHS Foundation Trust Sutton, Surrey, SM2 5PT

View Study

Consistent with Nurix’s mission to establish degrader-based medicines at the forefront of patient care, we are focused on enrolling and conducting our clinical trials and obtaining the regulatory approvals necessary to make our medicines available to patients as quickly as possible. We are privileged to collaborate with the clinical investigators and patients who participate in our studies to develop new, safe, and effective therapies. We believe this approach will serve patients who could be helped by the therapies we are developing.

Expanded access programs, also known as “pre-approval access” or “compassionate use”, are potential pathways for patients to receive investigational drugs that are not yet approved by the FDA or other regulatory authorities but may be beneficial for patients with serious or life-threatening conditions. Under these programs, patients who are unable to participate in a clinical trial may potentially receive the investigational drug outside of a clinical trial. Under the 21st Century Cures Act, the manufacturer or distributor of one or more investigational drugs for the treatment of one or more serious diseases or conditions shall make available its policy on how it evaluates and responds to requests submitted under section 561(b) of the Federal Food, Drug, and Cosmetic Act for provision of such a drug. The following is Nurix’s policy for responding to requests for expanded access to investigational drugs that are intended to treat serious diseases.

› NX-5948 Expanded Access Policy For questions about our programs and clinical trials, please contact us .